MLN2238
In December 2007, a wholly-owned second generation proteasome inhibitor, MLN2238, was advanced to the development pipeline. In pre-clinical models, MLN2238 showed superior efficacy relative to VELCADE with potential in a broader set of hematological and solid tumors. This molecule is expected to move forward in both oral and IV routes of administration.
